Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566309 | 1.00 | BAZ2B (0.46) | BAZ2BBAZ2AGAAHTTALDH1A1 | |
| SCHEMBL19500071 | 0.87 | TTR (0.47) | BAZ2BBAZ2AGAAHTTALDH1A1 | |
| SCHEMBL23952005 | 0.83 | BAZ2B (0.49) | BAZ2BBAZ2AGAAALDH1A1LMNA | |
| SCHEMBL13658710 | 0.83 | TDP1 (0.50) | GAAHTTALDH1A1APPGLA | |
| SCHEMBL12287050 | 0.83 | GLA (0.46) | GAAHTTALDH1A1APPGLA | |
| SCHEMBL9197132 | 0.82 | BAZ2B (0.47) | BAZ2BBAZ2AGAAALDH1A1LMNA | |
| SCHEMBL1081773 | 0.81 | ALDH1A1 (0.42) | BAZ2BBAZ2AGAAHTTALDH1A1 | |
| SCHEMBL1006833 | 0.81 | ALDH1A1 (0.42) | BAZ2BBAZ2AGAAHTTALDH1A1 | |
| SCHEMBL1006832 | 0.81 | ALDH1A1 (0.42) | BAZ2BBAZ2AGAAHTTALDH1A1 | |
| SCHEMBL1003723 | 0.80 | BAZ2B (0.51) | BAZ2BBAZ2AGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009125191-A1 | BENZENE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125191-A1 | BENZENE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | BAZ2B 3138/4885BAZ2A 3317/4885GAA 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.